Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Bleecker Bio (Formation) Licenses Lynk’s CNS‑Penetrant TYK2 Inhibitor LNK01006 in $605 M Deal

Fineline Cube Dec 11, 2025
Company Deals

Juncell Therapeutics Files for HKEX IPO, Pioneering Chemo‑Free TIL Therapy for Solid Tumors

Fineline Cube Dec 11, 2025
Company Deals

Relation Therapeutics and Novartis Forge $1.7 Billion Alliance for AI‑Driven Atopic Disease Targets

Fineline Cube Dec 11, 2025
Company Deals

Zealand Pharma and OTR Therapeutics Seal $2.5 Billion Metabolic Disease Partnership

Fineline Cube Dec 11, 2025
Company Deals

D3 Bio Closes $108 M Series B to Advance Elisrasib KRAS G12C Phase 3 Trials Globally

Fineline Cube Dec 10, 2025
Policy / Regulatory

NHSA 2025 Drug Lists Add 114 Medical Insurance Drugs, 19 Commercial

Fineline Cube Dec 8, 2025
Company Drug

Lobemilast (Y‑3) NDA Accepted by NMPA as First Multi‑Target Stroke Neuroprotectant

Fineline Cube Dec 12, 2025
Company Drug

Shanghai Pharma’s SPH3127 Renin Inhibitor Wins NMPA Approval for Primary Hypertension

Fineline Cube Dec 11, 2025
Company Drug

Hengrui Pharma and Kailera Announce Positive Phase III Results for HRS9531 in Obesity Treatment

Fineline Cube Jul 16, 2025

China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) and its US partner Kailera Therapeutics, Inc....

Company Drug

Haisco Pharma Receives FDA Approval for Clinical Trials of Autoimmune Drug HSK47388

Fineline Cube Jul 16, 2025

China-based Haisco Pharmaceutical Group Co., Ltd (SHE: 002653) announced that it has received clinical trial...

Company Deals

Danaher’s Cytiva Collaborates with CorrectSequence on Gene Therapy LNP Delivery System

Fineline Cube Jul 16, 2025

US-based science and tech services giant Danaher Corporation (NYSE: DHR) announced an ongoing collaboration between...

Company Drug

AstraZeneca’s Baxdrostat Meets Primary and Secondary Endpoints in Phase III BaxHTN Trial

Fineline Cube Jul 16, 2025

UK-based AstraZeneca (AZ, NASDAQ: AZN) announced that baxdrostat has achieved both primary and secondary endpoints in the...

Company Medical Device

Shanghai Sanyou Medical Receives NMPA Marketing License for JAZZ Spinal Fixation System

Fineline Cube Jul 16, 2025

Shanghai Sanyou Medical Co., Ltd (SHA: 688085) announced that it has received the marketing license...

Policy / Regulatory

NMPA Updates Reference Drugs for GQCE Evaluation: 42 New Additions and 6 Removals

Fineline Cube Jul 16, 2025

China’s National Medical Products Administration (NMPA) has released the 94th batch of reference drugs for...

Company Deals

BD Merges Biosciences & Diagnostic Solutions with Waters Corporation in USD 17.5 Billion Deal

Fineline Cube Jul 16, 2025

US major Becton, Dickinson and Co., (BD) is set to merge its Biosciences & Diagnostic...

Company Deals

Sino Biopharmaceutical Acquires Majority Stake in LaNova Medicines for USD 950.92 Million

Fineline Cube Jul 16, 2025

China-based Sino Biopharmaceutical Ltd (HKG: 1177) announced the acquisition of a 95.09% stake in Shanghai-based...

Company Drug

Vigonvita’s Simenafil Receives NMPA Approval for Erectile Dysfunction Treatment

Fineline Cube Jul 16, 2025

Suzhou-based Vigonvita Life Sciences Co., Ltd., announced that it has received marketing approval from the...

Company Deals

Xgene Licenses Novel Non-Opioid Analgesic XG005 to NeuroGen for Greater China Development

Fineline Cube Jul 16, 2025

Shanghai-based Xgene Pharmaceutical Inc. has entered into a licensing agreement withNeuroGen Pharma, a neurology care...

Company Deals

Otsuka to Acquire Cantargia’s IL-1RAP Monoclonal Antibody CAN10 for Autoimmune Diseases

Fineline Cube Jul 16, 2025

Japan-based drug maker Otsuka (OTCMKTS: OTSKY) is set to acquire from Swedish biotech Cantargia AB...

Company Drug

Huadong Medicine Receives FDA Approval for Clinical Trials of Innovative ADC HDM2020

Fineline Cube Jul 15, 2025

China-based Huadong Medicine Co., Ltd (SHE: 000963) announced that it has received clinical trial approval...

Company Deals

Ningbo Health Gene and Biofast Biotech Partner to Advance Genetic Testing for Hereditary Diseases

Fineline Cube Jul 15, 2025

Chinese firms Ningbo Health Gene Technologies Co., Ltd. and Biofast Biotechnology Co., Ltd. announced late...

Company Deals

Boehringer Ingelheim Licenses Spevigo to LEO Pharma for Global Dermatology Expansion

Fineline Cube Jul 15, 2025

German pharmaceutical giant Boehringer Ingelheim (BI) this week announced a licensing agreement with Denmark-based dermatology...

Company Medical Device

Peijia Medical Completes First Patient Implantation for MonarQ TTVR System in Global Clinical Study

Fineline Cube Jul 15, 2025

China-based Peijia Medical Ltd (HKG: 9996) announced the successful completion of the first patient implantation...

Company Deals

Golden Age Health Secures Exclusive Rights to Innostellar’s Gene Therapy LX-101 in China

Fineline Cube Jul 15, 2025

Singapore-based Golden Age Health, a specialty pharmaceutical company focused on rare and specialty diseases, has...

Company Drug

Merck Initiates EXPrESSIVE Phase III Trial for Once-Monthly HIV PrEP Drug MK-8527

Fineline Cube Jul 15, 2025

Merck, Sharp & Dohme Inc., (MSD; NYSE: MRK) announced the initiation of the EXPrESSIVE Phase...

Company Drug

China Medical System’s CMS-D001 Gains NMPA Approval for Atopic Dermatitis Trials

Fineline Cube Jul 15, 2025

China Medical System Holdings Limited (CMS; HKG: 0867) announced that it has received clinical trial...

Policy / Regulatory

NHSA Reports 2024 Healthcare Stats: BMI Fund Reaches RMB 3.49 Trillion Income with 95% Participation Rate

Fineline Cube Jul 15, 2025

The National Healthcare Security Administration (NHSA) this week released its national medical and healthcare development...

Company Drug

SinoMab BioScience Voluntarily Withdraws BLA for Suciraslimab in China Citing Need for Additional Data

Fineline Cube Jul 15, 2025

SinoMab BioScience Ltd (HKG: 3681) announced the voluntary withdrawal of its Biologics License Application (BLA)...

Posts pagination

1 … 57 58 59 … 596

Recent updates

  • Lobemilast (Y‑3) NDA Accepted by NMPA as First Multi‑Target Stroke Neuroprotectant
  • Bleecker Bio (Formation) Licenses Lynk’s CNS‑Penetrant TYK2 Inhibitor LNK01006 in $605 M Deal
  • Shanghai Pharma’s SPH3127 Renin Inhibitor Wins NMPA Approval for Primary Hypertension
  • Juncell Therapeutics Files for HKEX IPO, Pioneering Chemo‑Free TIL Therapy for Solid Tumors
  • Relation Therapeutics and Novartis Forge $1.7 Billion Alliance for AI‑Driven Atopic Disease Targets
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Lobemilast (Y‑3) NDA Accepted by NMPA as First Multi‑Target Stroke Neuroprotectant

Company Deals

Bleecker Bio (Formation) Licenses Lynk’s CNS‑Penetrant TYK2 Inhibitor LNK01006 in $605 M Deal

Company Drug

Shanghai Pharma’s SPH3127 Renin Inhibitor Wins NMPA Approval for Primary Hypertension

Company Deals

Juncell Therapeutics Files for HKEX IPO, Pioneering Chemo‑Free TIL Therapy for Solid Tumors

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.